The court has vacated all trial and pretrial deadlines in the bellwether case Toney v. Pfizer Inc., effectively signaling that a global settlement agreement has been reached in the Depo-Provera products liability litigation.
Plaintiffs' lead counsel and defendants Pfizer Inc., Pharmacia LLC, and Pharmacia & Upjohn Co. LLC have reached an agreement under which all plaintiffs with cases pending in the MDL who meet agreed eligibility criteria will have an opportunity to resolve their claims.
The court's order vacating deadlines filed on June 15, 2026, confirms the parties are now working to memorialize the details of that global agreement.
The settlement applies to cases pending in the MDL
On its face, the court's language limiting the global agreement to plaintiffs "with cases pending in this MDL who meet the eligibility criteria" reads as a hard docket lock cutting off any unfiled cases from participation. The parties note, however, that there is an important exception for inventory that is retained but not filed. Cases that were retained by counsel but not filed prior to the date of the order are still eligible to participate in the global settlement.
This distinction between pending cases and retained cases creates a practical boundary between protected and unprotected inventory. The door is effectively closed to new case acquisition and marketing after the order date. Your existing pre-litigation inventory is protected as long as the retainer agreement predates the June 15, 2026 order. Once the final master settlement agreement is in place, the registration window opens with strict eligibility cutoffs.
Strategic action required before registration window opens
The formal master settlement agreement is still being worked out while the parties finalize the global deal. This creates a tight window for firms to go through their Depo-Provera inventory and identify cases eligible for the settlement pool. Taking action now will determine whether your unfiled cases get into the global resolution:
- Immediate docket audit: Identify all Depo-Provera claimants currently under retainer whose complaints have not yet been filed or docketed in the MDL. This includes intake, cases waiting to be filed, and cases with executed retainers waiting to be prepared.
- Retainer dates: All executed client retainer agreements not yet filed must be dated before the vacating order of June 15, 2026. Retainer dates are what determine eligibility for protected status in the settlement pool.
- Document file status: Maintain clear documentation of which cases are pending in the MDL versus which cases are retained but unfiled. The parties will require this distinction during the registration process.
- Prepare for registration protocol: Stand by for the formal census or registration protocol that will be required to port these pre-litigation files into the settlement pool. The timing of registration will likely determine settlement valuation and claim prioritization.
Timing implications for settlement participation
The court order says the case eligibility ends June 15, 2026. Cases backed by retainer agreements dated before that cutoff are protected regardless of whether complaints have been filed. Cases brought in after the cutoff through new marketing or referrals do not qualify for the global settlement.
For firms holding unfiled Depo-Provera cases, the settlement framework offers a resolution opportunity through a structured process rather than individual litigation. The parties are working through the details now, and the framework is expected to spell out eligibility criteria, claim valuation methodology, and registration procedures once the master settlement agreement is done.
The move toward a master settlement agreement shows this litigation is heading toward resolution fast. Firms holding unfiled cases should get their audit and documentation in order before the registration window opens, as waiting too long to register protected inventory could affect both timing and how claims are treated.
Atraxia Media monitors MDL settlement developments
With the Depo-Provera litigation moving from active trials toward global settlement, plaintiff firms need to stay on top of filing deadlines and inventory eligibility to make the most of settlement participation. Atraxia Media tracks emerging settlement frameworks and litigation updates affecting plaintiff inventories across major MDLs.
If your firm holds unfiled Depo-Provera cases or is evaluating new case acquisition in concluded MDL litigation, contact Atraxia Media to discuss how we identify settlement eligibility and optimize your case positioning before registration deadlines close.